## Fiscal 2021 Supplementary Materials

## Table of Contents

## Consolidated Basis

Fiscal 2021 Statements of Income ..... $1 P$
Fiscal 2021 Statements of Income by Half ..... $2 P$
Fiscal 2022 Projected Statements of Income ..... $3 P$
Fiscal 2021 Sales Results by Product Line ..... 4 P
Fiscal 2022 Sales Plan by Product Line ..... 5 P
SG\&A (Actual and Forecast) ..... 6 P
Other Income/Expenses (Actual and Forecast)
Capital Expenditures and Depreciation Expenses ..... $7 P$
Balance Sheets (Major Changes)
Statements of Cash Flows ..... 8 P
Non-Consolidated Basis
Fiscal 2021 Statements of Income ..... 9 P
Fiscal 2021 Statements of Income by Half ..... 10 P
Fiscal 2022 Projected Statements of Income ..... 11 P
Total Manufacturing Costs ..... 12 P
(Notes Concerning Forward-Looking Statements) Projections throughout these materials are provided as a reference for investors. They are based on estimates and forecasts, and shall not be regarded as pledges or guarantees. They shall be used on the full acknowledgment that actual results may naturally differ from projections.

Fiscal 2021 Statements of Income (Consolidated)

| First Quarter |  |  |  |  | $¥$ millions, rounded down |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | June 2021 Results |  | June 2020 <br> Results |  | Year-on-Year Comparison |  |
|  | Amount | \% of total | Amount | \% of total | Amount | \% |
| Net sales | 8,895 | 100.0 | 8,376 | 100.0 | 519 | 106.2 |
| Cost of Sales | 5,115 | 57.5 | 4,874 | 58.2 | 241 | 105.0 |
| Gross profit | 3,780 | 42.5 | 3,502 | 41.8 | 277 | 107.9 |
| SG\&A expenses | 2,287 | 25.7 | 2,358 | 28.2 | $\triangle 70$ | 97.0 |
| Operating income | 1,492 | 16.8 | 1,143 | 13.7 | 348 | 130.5 |
| Other income | 34 |  | 109 |  | $\triangle 74$ |  |
| Other expenses | 31 |  | 1 |  | 30 |  |
| Ordinary income | 1,495 | 16.8 | 1,251 | 14.9 | 243 | 119.5 |
| Extraordinary income |  |  |  |  |  |  |
| Extraordinary expenses | 1 |  |  |  | 1 |  |
| Income berore Income taxes and minority interests | 1,494 | 16.8 | 1,251 | 14.9 | 242 | 119.4 |
| Corporation tax, etc. | 412 |  | 352 |  | 59 |  |
| (Tax burden) | 27.6\% |  | 28.1\% |  |  |  |
| Minority interests | $\triangle 7$ |  | $\triangle 8$ |  | 1 |  |
| Profit attributable to owners of parent | 1,089 | 12.2 | 908 | 10.8 | 181 | 120.0 |
| EPS (total shares) | ¥33.34 |  | *27.78 |  |  |  |
| EPS (minus treasury shares) | ¥36.65 |  | ¥30.04 |  |  |  |
| Number of shares outstanding Weighted-average number of shares | 32,682,310 |  | 32,682,310 |  |  |  |
| outstanding (after deducting treasury shares) | 29,729,200 |  | 30,223,453 |  |  |  |

First Half Results
$¥$ millions, rounded down

|  | $\begin{gathered} \text { Sept. } 2021 \\ \text { Interim Results } \end{gathered}$ |  | $\begin{gathered} \text { Sept. } 2020 \\ \text { Interim Results } \end{gathered}$ |  | Year-on-Year Comparison |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Amount | \% of total | Amount | \% of total | Amount | \% |
| Net sales | 17,928 | 100.0 | 17,734 | 100.0 | 193 | 101.1 |
| Cost of Sales | 10,344 | 57.7 | 10,374 | 58.5 | $\triangle 30$ | 99.7 |
| Gross profit | 7,583 | 42.3 | 7,360 | 41.5 | 223 | 103.0 |
| SG\&A expenses | 4,596 | 25.6 | 4,689 | 26.4 | $\triangle 92$ | 98.0 |
| Operating income | 2,987 | 16.7 | 2,671 | 15.1 | 316 | 111.8 |
| Other income | 151 |  | 138 |  | 13 |  |
| Other expenses | 72 |  | 3 |  | 68 |  |
| Ordinary income | 3,067 | 17.1 | 2,806 | 15.8 | 261 | 109.3 |
| Extraordinary income |  |  | 1,028 |  | $\triangle 1,028$ |  |
| Extraordinary expenses | 1 |  | 1 |  | $\triangle 0$ |  |
| Income before income taxes and minority interests | 3,065 | 17.1 | 3.833 |  |  |  |
| Corporation tax, etc. | 846 |  | 1,068 |  | $\triangle 221$ |  |
| (Tax burden) | 27.6\% |  | 27.9\% |  |  |  |
| Minority interests | $\triangle 15$ |  | $\triangle 11$ |  | $\triangle 3$ |  |
| Profit attributable to owners of parent | 2,234 | 12.5 | 2,776 | 15.7 | $\triangle 541$ | 80.5 |
| EPS (total shares) | $\underset{ }{768.36}$ |  | ¥84.94 |  |  |  |
| EPS (minus treasury shares) | ¥75.83 |  | ¥91.84 |  |  |  |
| Number of shares outstanding weignted-average number or shares | 32,682,310 |  | 32,682,310 |  |  |  |
| outstanding (after deducting treasury shares) | 29,461,490 |  | 30,228,126 |  |  |  |



| EPS (total shares) | $\neq 126.99$ | $\neq 126.27$ |
| :--- | :---: | ---: |
| EPS (minus treasury shares) | $\neq 12142.11$ |  |
| Number of shares outstanding | $32,682,310$ | $32,682,310$ |
| welgnted-average number or shares |  |  |


| Full-year |  |  |  |  |  |  |  |  | millions, rounded down |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Fiscal 2021Results |  | $\begin{aligned} & \hline \text { Fiscal } 2020 \\ & \text { Results } \end{aligned}$ |  | Year-on-Year Comparison |  | Fiscal 2021 <br> Revised Plan |  | Revised Plan Comparison |  |
|  | Amount | \% of total | Amount | \% of total | Amount | \% | Amount | \% of total | Amount | \% |
| Net sales | 36,778 | 100.0 | 36,504 | 100.0 | 273 | 100.8 | 36,570 | 100.0 | 208 | 100.6 |
| Cost of Sales | 21,361 | 58.1 | 21,177 | 58.0 | 183 | 100.9 | 21,300 | 58.2 | 61 | 100.3 |
| Gross profit | 15,416 | 41.9 | 15,326 | 42.0 | 89 | 100.6 | 15,270 | 41.8 | 146 | 101.0 |
| SG\&A expenses | 9,281 | 25.2 | 9,694 | 26.6 | $\triangle 412$ | 95.7 | 9,480 | 25.9 | $\triangle 198$ | 97.9 |
| Operating income | 6,135 | 16.7 | 5,632 | 15.4 | 502 | 108.9 | 5,790 | 15.8 | 345 | 106.0 |
| Other income | 406 |  | 421 |  | $\triangle 15$ |  | 410 |  | $\triangle 3$ |  |
| Other expenses | 255 |  | 65 |  | 189 |  | 150 |  | 105 |  |
| Ordinary income | 6,285 | 17.1 | 5,988 | 16.4 | 297 | 105.0 | 6,050 | 16.5 | 235 | 103.9 |
| Extraordinary income | 1 |  | 1,030 |  | $\triangle 1,028$ |  |  |  | 1 |  |
| Extraordinary expenses | 1 |  | 28 |  | $\triangle 27$ |  | 10 |  | $\triangle 8$ |  |
| Income before income taxes and minority interests | 6,286 | 17.1 | 6,989 | 19.1 | $\triangle 703$ | 89.9 | 6,040 | 16.5 | 246 | 104.1 |
| Corporation tax, etc. | 1,951 |  | 2,060 |  | $\triangle 108$ |  | 1,780 |  | 171 |  |
| (Tax burden) | 31.1\% |  | 29.5\% |  |  |  | 29.5\% |  |  |  |
| Minority interests | $\triangle 35$ |  | $\triangle 30$ |  | $\triangle 5$ |  | $\triangle 40$ |  | 4 |  |
| Profit attributable to owners of parent | 4,370 | 11.9 | 4,959 | 13.6 | $\triangle 588$ | 88.1 | 4,300 | 11.8 | 70 | 101.6 |
| EPS (total shares) | *133.72 |  | \#151.73 |  |  |  | ¥131.57 |  |  |  |
| EPS (minus treasury shares) | ¥153.00 |  | ¥164.03 |  |  |  | ¥150.54 |  |  |  |
| Number of shares outstanding Weighted-average number of shares | 32,682,310 |  | 32,682,310 |  |  |  | 32,682,310 |  |  |  |
| outstanding (after deducting treasury shares) | 28,563,593 |  | 30,231,715 |  |  |  | 28,563,593 |  |  |  |

Fiscal 2021 Statements of Income by Quarter (Consolidated)

|  | $\begin{aligned} & \text { First } \\ & \text { Quarter } \end{aligned}$ | Second Quarter | Third Quarter | Fourth Quarter |
| :---: | :---: | :---: | :---: | :---: |
| Net sales | 8,895 | 9,032 | 9,882 | 8,967 |
| Cost of Sales | 5,115 | 5,228 | 5,688 | 5,329 |
| Gross profit | 3,780 | 3,803 | 4,194 | 3,638 |
| SG\&A expenses | 2,287 | 2,308 | 2,379 | 2,305 |
| Operating income | 1,492 | 1,494 | 1,814 | 1,332 |
| Other income | 34 | 117 | 238 | 16 |
| Other expenses | 31 | 40 | 47 | 135 |
| Ordinary income | 1,495 | 1,571 | 2,004 | 1,213 |
| Extraordinary income |  |  | 1 |  |
| Extraordinary expenses | 1 | 0 | 0 | 0 |
| Income before income taxes and minority interests | 1,494 | 1,571 | 2,006 | 1,213 |
| Corporation tax, etc. | 412 | 434 | 556 | 548 |
| (Tax burden) | 27.6\% | 27.7\% | 27.7\% | 45.2\% |
| Minority interests | $\triangle 7$ | $\triangle 7$ | $\triangle 8$ | $\triangle 11$ |
| Profit attributable to owners of parent | 1,089 | 1,144 | 1,458 | 677 |


| ¥ millions, rounded down |  |  |
| :---: | :---: | :---: |
| First Half | Third Quarter (Cumulative) | Full-year |
| 17,928 | 27,810 | 36,778 |
| 10,344 | 16,032 | 21,361 |
| 7,583 | 11,778 | 15,416 |
| 4,596 | 6,976 | 9,281 |
| 2,987 | 4,802 | 6,135 |
| 151 | 390 | 406 |
| 72 | 120 | 255 |
| 3,067 | 5,072 | 6,285 |
|  | 1 | 1 |
| 1 | 1 | 1 |
| 3,065 | 5,072 | 6,286 |
| 846 | 1,403 | 1,951 |
| 27.6\% | 27.7\% | 31.1\% |
| $\triangle 15$ | $\triangle 24$ | $\triangle 35$ |
| 2,234 | 3,692 | 4,370 |

Fiscal 2020

|  | $\begin{aligned} & \text { First } \\ & \text { Quarter } \end{aligned}$ | Second Quarter | $\begin{aligned} & \text { Thira } \\ & \text { Quarter } \end{aligned}$ | Fourth Quarter |
| :---: | :---: | :---: | :---: | :---: |
| Net sales | 8,376 | 9,358 | 9,961 | 8,807 |
| Cost of Sales | 4,874 | 5,499 | 5,695 | 5,107 |
| Gross profit | 3,502 | 3,858 | 4,265 | 3,700 |
| SG\&A expenses | 2,358 | 2,331 | 2,429 | 2,576 |
| Operating income | 1,143 | 1,527 | 1,836 | 1,124 |
| Other income | 109 | 29 | 279 |  |
| Other expenses | 1 | 1 | 2 | 59 |
| Ordinary income | 1,251 | 1,554 | 2,113 | 1,068 |
| Extraordinary income |  | 1,028 |  |  |
| Extraordinary expenses |  | 1 | 1 | 25 |
| Income before income taxes and minority interests | 1,251 | 2,581 | 2,111 | 1,044 |
| Corporation tax, etc. | 352 | 716 | 598 | 393 |
| (Tax burden) | 28.1\% | 27.7\% | 28.3\% | 37.7\% |
| Minority interests | $\triangle 8$ | $\triangle 2$ | $\triangle 6$ | $\triangle 11$ |
| Profit attributable to owners of parent | 908 | 1,868 | 1,520 | 662 |


| Trird <br> First Hallions, rounded down <br> (Cumulative) |  |  |
| ---: | ---: | ---: |
| 17,734 | 27,696 | Full-year |
| 10,374 | 16,070 | 21,177 |
| 7,360 | 11,626 | 15,326 |
| 4,689 | 7,118 | 9,694 |
| 2,671 | 4,508 | 5,632 |
| 138 | 417 | 421 |
| 3 | 6 | 65 |
| 2,806 | 4,919 | 5,988 |
| 1,028 | 1,028 | 1,030 |
| 1 | 3 | 28 |
| 3,833 | 5,945 | 6,989 |
| 1,068 | 1,667 | 2,060 |
| $27.9 \%$ | $28.0 \%$ | $29.5 \%$ |
| $\triangle 11$ | $\triangle 18$ | $\triangle 30$ |
| 2,776 | 4,296 | 4,959 |
|  |  |  |

## Change(Amount)

|  | $\begin{gathered} \text { First } \\ \text { Quarter } \end{gathered}$ | Second Quarter | $\begin{aligned} & \text { Third } \\ & \text { Quarter } \end{aligned}$ | Fourth Quarter |
| :---: | :---: | :---: | :---: | :---: |
| Net sales | 519 | $\triangle 325$ | $\triangle 79$ | 159 |
| Cost of Sales | 241 | $\triangle 271$ | $\triangle 7$ | 221 |
| Gross profit | 277 | $\triangle 54$ | $\triangle 71$ | $\triangle 61$ |
| SG\&A expenses | $\triangle 70$ | $\triangle 22$ | $\triangle 49$ | $\triangle 270$ |
| Operating income | 348 | $\triangle 32$ | $\triangle 22$ | 208 |
| Other income | $\triangle 74$ | 88 | $\triangle 40$ | 11 |
| Other expenses | 30 | 38 | 44 | 76 |
| Ordinary income | 243 | 17 | $\triangle 108$ | 144 |
| Extraordinary income |  | $\triangle 1,028$ | 1 | $\triangle 1$ |
| Extraordinary expenses | 1 | $\triangle 1$ | $\triangle 1$ | $\triangle 25$ |
| Income berore Income taxes and minority interests | 242 | $\triangle 1,010$ | $\triangle 104$ | 169 |
| Corporation tax, etc. | 59 | $\triangle 281$ | $\triangle 41$ | 154 |
| (Tax burden) |  |  |  |  |
| Minority interests | 1 | $\triangle 5$ | $\triangle 1$ | 0 |
| Profit attributable to owners of parent | 181 | $\triangle 723$ | $\triangle 61$ | 14 |


| First Half | ThirdQuarter <br> (Cumulative) | Full-year |
| ---: | ---: | ---: |
| 193 | 114 | 273 |
| $\triangle 30$ | $\triangle 37$ | 183 |
| 223 | 151 | 89 |
| $\triangle 92$ | $\triangle 142$ | $\triangle 412$ |
| 316 | 293 | 502 |
| 13 | $\triangle 27$ | $\Delta 15$ |
| 68 | 113 | 189 |
| 261 | 152 | 297 |
| $\triangle 1,028$ | $\triangle 1,027$ | $\triangle 1,028$ |
| $\triangle 0$ | $\triangle 1$ | $\triangle 27$ |
| $\triangle 767$ | $\triangle 872$ | $\triangle 703$ |
| $\triangle 221$ | $\triangle 263$ | $\triangle 108$ |
|  |  |  |
| $\triangle 3$ | $\triangle 5$ | $\triangle 5$ |
| $\triangle 541$ | $\triangle 603$ | $\triangle 588$ |

Change(\%)

|  | $\begin{aligned} & \text { First } \\ & \text { Quarter } \end{aligned}$ | second Quarter | $\begin{aligned} & \text { Thira } \\ & \text { Quarter } \end{aligned}$ | Fourth Quarter |
| :---: | :---: | :---: | :---: | :---: |
| Net sales | 106.2 | 96.5 | 99.2 | 101.8 |
| Cost of Sales | 105.0 | 95.1 | 99.9 | 104.3 |
| Gross profit | 107.9 | 98.6 | 98.3 | 98.3 |
| SG\&A expenses | 97.0 | 99.1 | 98.0 | 89.5 |
| Operating income | 130.5 | 97.9 | 98.8 | 118.6 |
| Other income |  |  |  |  |
| Other expenses |  |  |  |  |
| Ordinary income | 119.5 | 101.1 | 94.9 | 113.5 |
| Extraordinary income |  |  |  |  |
| Extraordinary expenses |  |  |  |  |
| Income before income taxes and minority interests | 119.4 | 60.9 | 95.0 | 116.2 |
| Corporation tax, etc. |  |  |  |  |
| (Tax burden) |  |  |  |  |
| Minority interests |  |  |  |  |
| Profit attributable to owners of parent | 120.0 | 61.3 | 96.0 | 102.2 |


| First Half | ThirdQuarter <br> (Cumulative) | Full-year |
| ---: | ---: | ---: |
| 101.1 | 100.4 | 100.8 |
| 99.7 | 99.8 | 100.9 |
| 103.0 | 101.3 | 100.6 |
| 98.0 | 98.0 | 95.7 |
| 111.8 | 106.5 | 108.9 |
|  |  |  |
|  |  |  |
| 109.3 | 103.1 | 105.0 |
|  |  |  |
|  |  |  |
| 80.0 | 85.3 | 89.9 |
|  |  |  |
|  |  |  |
| 80.5 | 86.0 | 88.1 |


|  | $\begin{aligned} & \text { First } \\ & \text { Quarter } \end{aligned}$ | Second Quarter | $\begin{aligned} & \text { Third } \\ & \text { Quarter } \end{aligned}$ | Fourth Quarter |
| :---: | :---: | :---: | :---: | :---: |
| Net sales | 100.0 | 100.0 | 100.0 | 100.0 |
| Cost of Sales | 57.5 | 57.9 | 57.6 | 59.4 |
| Gross profit | 42.5 | 42.1 | 42.4 | 40.6 |
| SG\&A expenses | 25.7 | 25.6 | 24.1 | 25.7 |
| Operating income | 16.8 | 16.6 | 18.4 | 14.9 |
| Other income |  |  |  |  |
| Other expenses |  |  |  |  |
| Ordinary income | 16.8 | 17.4 | 20.3 | 13.5 |
| Extraordinary income |  |  |  |  |
| Extraordinary expenses |  |  |  |  |
| Income before income taxes and minority interests | 16.8 | 17.4 | 20.3 | 13.5 |
| Corporation tax, etc. |  |  |  |  |
| (Tax burden) |  |  |  |  |
| Minority interests |  |  |  |  |
| Profit attributable to owners of parent | 12.2 | 12.7 | 14.8 | 7.6 |


| First Half | ThirdQuarter <br> (Cumulative) | Full-year |
| ---: | ---: | ---: |
| 100.0 | 100.0 | 100.0 |
| 57.7 | 57.6 | 58.1 |
| 42.3 | 42.4 | 41.9 |
| 25.6 | 25.1 | 25.2 |
| 16.7 | 17.3 | 16.7 |
|  |  |  |
| 17.1 | 18.2 | 17.1 |
|  |  |  |
|  |  |  |
| 17.1 | 18.2 | 17.1 |
|  |  |  |
|  |  |  |
|  |  |  |
| 12.5 | 13.3 | 11.9 |

Fiscal 2022 Projected Statements of Income
Cumulative
$¥$ millions, rounded down,(\%)

|  | First Half | \% of total | Full-year | \% of total |
| :---: | :---: | :---: | :---: | :---: |
| Net sales | 19,070 | 100.0 | 38,720 | 100.0 |
| Operating income | 3,170 | 16.6 | 6,510 | 16.8 |
| Ordinary income | 3,210 | 16.8 | 6,570 | 17.0 |
| Profit attributable to owners of parent | 2,250 | 11.8 | 4,570 | 11.8 |
| EPS (before deducting treasury shares) | $¥ 68.84$ |  | $¥ 139.83$ |  |
| EPS (minus treasury shares) | $¥ 92.76$ |  | $¥ 188.40$ |  |
|  | Number of shares outstanding |  | 32,682,310 |  |
|  | Shares outstanding at FY2021year-end |  | 24,257,103 |  |
| Fiscal 2021 Results | (deducting treasury shares) |  |  |  |
| Net sales | 17,928 | 100.0 | 36,778 | 100.0 |
| Operating income | 2,987 | 16.7 | 6,135 | 16.7 |
| Ordinary income | 3,067 | 17.1 | 6,285 | 17.1 |
| Profit attributable to owners of parent | 2,234 | 12.5 | 4,370 | 11.9 |

Change (Amount and \%)

| Net sales | 1,141 | 106.4 | 1,941 | 105.3 |
| :--- | ---: | ---: | ---: | ---: |
| Operating income | 182 | 106.1 | 374 | 106.1 |
| Ordinary income | 142 | 104.7 | 284 | 104.5 |
| Profit attributable to owners of parent | 15 | 100.7 | 199 | 104.6 |

Fiscal 2021 Sales by Product Grouping
First Half Results
$¥$ millions, rounded down

|  | Sept. 2021 <br> Interim Results |  | Sept. 2020 <br> Interim Results |  | Year-on-Year Comparison |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Amount | \% of total | Amount | \% of total | Amount | \% |
| Sterilization products | 1,625 | 9.1 | 1,639 | 9.2 | $\triangle 13$ | 99.2 |
| Surgical products | 15,851 | 88.4 | 15,646 | 88.2 | 204 | 101.3 |
| Treatment products | 87 | 0.5 | 111 | 0.6 | $\triangle 23$ | 78.7 |
| Others | 363 | 2.0 | 337 | 1.9 | 26 | 107.7 |
| Total | 17,928 | 100.0 | 17,734 | 100.0 | 193 | 101.1 |
| Itemized surgical products |  |  |  |  |  |  |
| Non-woven products | 4,084 | 22.8 | 4,495 | 25.3 | $\triangle 410$ | 90.9 |
| Other non-woven products | 754 | 4.2 | 882 | 5.0 | $\triangle 127$ | 85.6 |
| Kit products | 10,924 | 60.9 | 10,193 | 57.5 | 730 | 107.2 |
| New products | 88 | 0.5 | 75 | 0.4 | 12 | 117.1 |
| Itemized external sales by subsidiary |  |  |  |  |  |  |
| Non-woven products | 311 |  | 249 |  | 61 |  |
| Other non-woven products | - |  | 27 |  | $\triangle 27$ |  |
| Kit products | 1 |  | 0 |  | 0 |  |
| Others | 41 |  | 36 |  | 5 |  |

Third Quarter $\quad ¥$ millions, rounded down

|  | Dec. 2021 <br> Interim Results |  | Dec. 2020 <br> Interim Results |  | Dec. 2020 <br> Interim Results |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Amount | \% of total | Amount | \% of total | Amount | \% |
| Sterilization products | 2,515 | 9.0 | 2,512 | 9.1 | 2 | 100.1 |
| Surgical products | 24,608 | 88.5 | 24,498 | 88.5 | 109 | 100.4 |
| Treatment products | 131 | 0.5 | 169 | 0.6 | $\triangle 38$ | 77.3 |
| Others | 555 | 2.0 | 515 | 1.9 | 39 | 107.7 |
| Total | 27,810 | 100.0 | 27,696 | 100.0 | 114 | 100.4 |
| Itemized surgical products |  |  |  |  |  |  |
| Non-woven products | 6,306 | 22.7 | 7,024 | 25.4 | $\triangle 717$ | 89.8 |
| Other non-woven products | 1,068 | 3.8 | 1,310 | 4.7 | $\triangle 242$ | 81.5 |
| Kit products | 17,087 | 61.4 | 16,048 | 57.9 | 1,038 | 106.5 |
| New products | 145 | 0.5 | 114 | 0.4 | 31 | 127.4 |
| Itemized external sales by subsidiary |  |  |  |  |  |  |
| Non-woven products | 492 |  | 414 |  | 77 |  |
| Other non-woven products | - |  | 38 |  | $\triangle 38$ |  |
| Kit products | 3 |  | 0 |  | 2 |  |
| Others | 63 |  | 51 |  | 12 |  |

Full-year
$\not \approx$ millions, rounded down

|  | Fiscal 2021 Results |  | Fiscal 2020 Results |  | Year-on-Year <br> Comparison |  | Fiscal 2021 Revised Plan |  | Revised Plan Comparison |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Amount | \% of total | Amount | \% of total | Amount | \% | Amount | \% of total | Amount | \% |
| Sterilization products | 3,362 | 9.1 | 3,266 | 8.9 | 95 | 102.9 | 3,340 | 9.1 | 22 | 100.7 |
| Surgical products | 32,502 | 88.4 | 32,340 | 88.6 | 161 | 100.5 | 32,290 | 88.3 | 212 | 100.7 |
| Treatment products | 178 | 0.5 | 215 | 0.6 | $\triangle 37$ | 82.7 | 180 | 0.5 | $\triangle 1$ | 99.1 |
| Others | 735 | 2.0 | 681 | 1.9 | 54 | 108.0 | 760 | 2.1 | $\triangle 24$ | 96.8 |
| Total | 36,778 | 100.0 | 36,504 | 100.0 | 273 | 100.8 | 36,570 | 100.0 | 208 | 100.6 |
| Itemized surgical products |  |  |  |  |  |  |  |  |  |  |
| Non-woven products | 8,230 | 22.4 | 9,283 | 25.4 | $\triangle 1052$ | 88.7 | 8,150 | 22.3 | 80 | 101.0 |
| Other non-woven products | 1,497 | 4.1 | 1,680 | 4.6 | $\triangle 182$ | 89.1 | 1,460 | 4.0 | 37 | 102.5 |
| Kit products | 22,557 | 61.3 | 21,187 | 58.0 | 1370 | 106.5 | 22,530 | 61.6 | 27 | 100.1 |
| New products | 216 | 0.6 | 190 | 0.5 | 26 | 114.1 | 150 | 0.4 | 66 | 144.5 |
| Itemized external sales by subsidiary |  |  |  |  |  |  |  |  |  |  |
| Non-woven products | 614 |  | 612 |  | 1 |  | 670 |  | $\triangle 55$ |  |
| Other non-woven products | 0 |  | 38 |  | $\triangle 38$ |  | - |  | 0 |  |
| Kit products | 4 |  | 0 |  | 3 |  | - |  | 4 |  |
| Others | 85 |  | 62 |  | 23 |  | 80 |  | 5 |  |

Sales Composition by Kit Treatment Category



|  | $¥$ millions, rounded down |  |
| :--- | ---: | ---: |
|  | First Half | Full-year |
| Sterilization products | 1,657 | 3,325 |
| Surgical products | 16,959 | 34,485 |
| Treatment products | 84 | 168 |
| Others | 369 | 741 |
| Total | 19,070 | 38,720 |

Itemized surgical products

| Non-woven products | 3,899 | 7,835 |
| :--- | ---: | ---: |
| Other non-woven products | 620 | 1,250 |
| Kit products | 12,270 | 25,050 |
| New products | 170 | 350 |

Itemized external sales by subsidiary

| Non-woven products | 259 | 535 |
| :--- | ---: | ---: |
| Other non-woven products | - | - |
| Kit products | - | - |
| Others | 41 | 85 |


|  |  | $\not \approx$ millions, rounded down |  |
| :--- | :--- | ---: | :---: |
|  | First Half | Full-year |  |
| Change(Amount) | 31 | $\triangle 36$ |  |
| Sterilization products | 1,107 | 1,982 |  |
| Surgical products | $\triangle 3$ | $\triangle 10$ |  |
| Treatment products | 6 | 5 |  |
| Others | 1,141 | 1,941 |  |
| Total |  |  |  |


| Itemized surgical products |  |  |
| :--- | ---: | ---: |
| Non-woven products | $\triangle 185$ | $\triangle 395$ |
| Other non-woven products | $\triangle 134$ | $\triangle 247$ |
| Kit products | 1,345 | 2,492 |
| New products | 81 | 133 |

Itemized external sales by subsidiary

| Non-woven products | $\triangle 52$ | $\triangle 79$ |
| :--- | ---: | ---: |
| Other non-woven products | - | $\triangle 0$ |
| Kit products | $\triangle 1$ | $\triangle 4$ |
| Others | $\triangle 0$ | $\triangle 0$ |


|  | (\%) |  |
| :--- | ---: | ---: |
| Breakdown | First Half | Full-year |
| Sterilization products | 8.7 | 8.6 |
| Surgical products | 88.9 | 89.1 |
| Treatment products | 0.4 | 0.4 |
| Others | 1.9 | 1.9 |
| Total |  | 100.0 |
| Itemized surgical products | 100.0 |  |
| Non-woven products |  |  |
| Other non-woven products | 20.4 | 20.2 |
| Kit products | 3.3 | 3.2 |
| New products | 64.3 | 64.7 |
|  | 0.9 | 0.9 |
| Itemized external sales by subsidiary |  |  |
| Non-woven products |  |  |
| Other non-woven products | 1.4 | 1.4 |
| Kit products | 0.0 | 0.0 |
| Others | 0.0 | 0.0 |
|  | 0.2 | 0.2 |

SG\&A and Other Income/Expenses (Actual and Forecast, Consolidated)
SG\&A Expenses
$¥$ millions, rounded down

|  | Fiscal 2021 <br> Results | Fiscal 2020 <br> Results | Year-on-Year Comparison | Fiscal 2021 <br> Revised Plan | Revised Plan Comparison | $\begin{gathered} \text { Fiscal } 2022 \\ \text { Plan } \end{gathered}$ | Year-on-Year Comparison |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Packaging and transportation | 1,064 | 1,075 | $\triangle 11$ | 1,057 | 7 | 1,112 | 47 |
| Losses on doubtful accounts | - | - | - | - |  |  |  |
| Samples | 299 | 355 | $\triangle 56$ | 361 | $\triangle 62$ | 362 | 62 |
| Advertising | 58 | 47 | 10 | 68 | $\triangle 9$ | 72 | 13 |
| Personnel | 4,025 | 4,050 | $\triangle 24$ | 4,066 | $\triangle 40$ | 4,112 | 86 |
| Travel | 426 | 391 | 35 | 453 | $\triangle 26$ | 461 | 34 |
| Communication | 147 | 138 | 9 | 149 | $\triangle 1$ | 146 | $\triangle 1$ |
| Consumables | 60 | 82 | $\triangle 22$ | 63 | $\triangle 2$ | 62 | 1 |
| Taxes and public charges | 326 | 338 | $\triangle 11$ | 339 | $\triangle 12$ | 340 | 13 |
| Depreciation | 805 | 906 | $\triangle 100$ | 860 | $\triangle 54$ | 859 | 53 |
| Testing and research | 417 | 648 | $\triangle 230$ | 483 | $\triangle 65$ | 459 | 41 |
| Land and housing rent | 451 | 435 | 16 | 447 | 4 | 474 | 22 |
| Miscellaneous | 456 | 549 | $\triangle 93$ | 448 | 8 | 468 | 12 |
| Others | 740 | 673 | 67 | 682 | 57 | 739 | $\triangle 1$ |
| Total | 9,281 | 9,694 | $\triangle 412$ | 9,480 | $\triangle 198$ | 9,670 | 388 |

Other Income/Expenses
$\left.\begin{array}{|l|r|r|r|r|r|r|r|}\hline & \begin{array}{c}\text { Fiscal 2021 } \\ \text { Results }\end{array} & \begin{array}{c}\text { Fiscal 2020 } \\ \text { Results }\end{array} & \begin{array}{c}\text { Year-on-Year } \\ \text { Comparison }\end{array} & \begin{array}{c}\text { Fiscal 2021 } \\ \text { Revised Plan }\end{array} & \begin{array}{c}\text { Revised Plan } \\ \text { Comparison }\end{array} & \begin{array}{c}\text { Fiscal 2022 } \\ \text { Plan }\end{array} \\ \hline \text { Comparison }\end{array}\right\}$

## Capital Expenditures and Depreciation Expenses (Actual and Forecast, Consolidated)

| Capital Expenditures |  |  | Depreciation Expenses |  |  |  |  | $¥$ millions, rounded down |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Capital Expenditures | Year-on-Year Comparison |  | SG\&A Expenses | Year-on-Year Comparison | Manufacturing Costs | Year-on-Year Comparison | Total Depreciation | Year-on-Year Comparison |
| Fiscal 2009 | 3,717 | 128.5 | Fiscal 2009 | 715 | 96.1 | 1,842 | 84.0 | 2,557 | 87.1 |
| Fiscal 2010 | 4,311 | 116.0 | Fiscal 2010 | 642 | 89.8 | 1,634 | 88.7 | 2,277 | 89.0 |
| Fiscal 2011 | 1,637 | 38.0 | Fiscal 2011 | 724 | 112.8 | 2,340 | 143.2 | 3,064 | 134.6 |
| Fiscal 2012 | 1,915 | 117.0 | Fiscal 2012 | 844 | 116.6 | 2,127 | 90.9 | 2,971 | 97.0 |
| Fiscal 2013 | 7,174 | 374.6 | Fiscal 2013 | 922 | 109.2 | 1,942 | 91.3 | 2,865 | 96.4 |
| Fiscal 2014 | 15,082 | 210.2 | Fiscal 2014 | 951 | 103.1 | 1,757 | 90.5 | 2,708 | 94.5 |
| Fiscal 2015 | 9,080 | 60.2 | Fiscal 2015 | 1,044 | 109.8 | 2,331 | 132.7 | 3,376 | 124.7 |
| Fiscal 2016 | 6,649 | 73.2 | Fiscal 2016 | 1,007 | 96.5 | 3,402 | 145.9 | 4,409 | 130.6 |
| Fiscal 2017 | 2,142 | 32.2 | Fiscal 2017 | 914 | 90.8 | 5,320 | 156.4 | 6,235 | 141.4 |
| Fiscal 2018 | 3,364 | 157.0 | Fiscal 2018 | 998 | 109.2 | 4,632 | 87.1 | 5,631 | 90.3 |
| Fiscal 2019 | 10,904 | 324.1 | Fiscal 2019 | 1,070 | 107.2 | 4,212 | 90.9 | 5,283 | 93.8 |
| Fiscal 2020 | 5,261 | 48.2 | Fiscal 2020 | 906 | 84.7 | 3,643 | 86.5 | 4,549 | 86.1 |
| Fiscal 2021 | 3,489 | 66.3 | Fiscal 2021 | 805 | 88.9 | 3,309 | 90.8 | 4,115 | 90.5 |
| Fiscal 2022 | 2,520 | 72.2 | Fiscal 2022 | 859 | 106.7 | 3,590 | 108.5 | 4,449 | 108.1 |

Note: Figures for Fiscal 2022 are Company forecasts.

[^0]
## Balance Sheets (Major Changes)/Statements of Cash Flows (Consolidated)

Major Changes on Balance Sheets

|  | Balance at <br> March 31, 2022 | Change |  | Balance at March 31, 2022 | Change |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Current assets | 35,290 | $\triangle$ 6,031 | Current liabilities | 9,348 | 1,758 |
| Cash and bank deposits | 14,364 | $\triangle 6,185$ | Notes and accounts payable | 4,336 | $\triangle 278$ |
| Notes and accounts receivable | 11,341 | $\triangle 49$ | Accrued expenses | 628 | 265 |
| Short-term investments | - | - | Long-term loans due within 1 year | 1,999 | 1934 |
| Inventories | 8,811 | 6 | Income taxes | 980 | $\triangle 126$ |
| Others | 773 | 196 | Allowance for employees' bonuses | 478 | $\triangle 41$ |
|  |  |  | Payable notes for equipment | 337 | 71 |
|  |  |  | Reserve for disaster loss |  |  |
|  |  |  | Others | 587 | $\triangle 64$ |
| Fixed assets | 63,676 | $\triangle 645$ | Long-term liabilities | 9,622 | 7,519 |
| Property, plant and equipment | 52,759 | $\triangle 35$ | Long-term borrowings | 7,667 | 7,667 |
| Buildings and structures | 21,578 | $\triangle 755$ | Others | 1,954 | $\triangle 148$ |
| Machinery, equipment and vehicles | 6,073 | $\triangle 1,094$ | Total liabilities | 18,970 | 9,278 |
| Land | 9,625 | 45 | Total net assets | 79,996 | $\triangle 15,955$ |
| Construction in progress | 14,775 | 2,078 | Common stock | 7,123 |  |
| Others | 706 | $\triangle 309$ | Capital surplus | 8,336 | 0 |
| Intangibles | 1,536 | $\triangle 415$ | Retained earnings | 88,523 | 2,374 |
| Investments and others | 9,381 | $\triangle 194$ | Treasury stock | $\triangle 27,561$ | $\triangle 18,658$ |
| Investments securities | 8,030 | 43 | Others | 3,574 | 328 |
| Others | 1,350 | $\triangle 238$ |  |  |  |
| Total assets | 98,967 | $\triangle 6,677$ | Total liabilities and shareholders' equity | 98,967 | $\triangle 6,677$ |

*Comparison with end of previous fiscal year:
Equity ratio increased from $90.76 \%$ at the end of the previous fiscal year to $80.79 \%$.

| Statements of Cash Flows | $¥$ millions, rounded down |  |  |
| :---: | :---: | :---: | :---: |
| I Operating activities | 8,501 | Income before income taxes <br> Depreciation <br> Income taxes paid | 6,286 4,115 $\triangle 2,089$ |
| II Investing activities | $\triangle 3,812$ | Proceeds from sales of investment securities Purchase of tangible fixed assets | $\begin{array}{r} \triangle 3,048 \\ \triangle 871 \end{array}$ |
| III Financing activities | $\triangle 11,049$ | Purchase of treasury stock Cash devidends paid | $\begin{array}{r} \triangle 18,773 \\ \triangle 1,995 \end{array}$ |
| IV Effect of exchange rate changes | 269 |  |  |
| Net changes in cash and cash equivalents | $\triangle 6,091$ |  |  |

## Fiscal 2021 Statements of Income by Half (Non-Consolidated)

| First Quarter |  |  |  |  | \# millions, rounded down |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | June 2021 Results |  | June 2020 <br> Results |  | Year-on-Year Comparison |  |
|  | Amount | \% of total | Amount | \% of total | Amount | \% |
| Net sales | 8,713 | 100.0 | 8,292 | 100.0 | 420 | 105.1 |
| Cost of Sales | 5,109 | 58.6 | 4,965 | 59.9 | 144 | 102.9 |
| Gross profit | 3,603 | 41.4 | 3,327 | 40.1 | 276 | 108.3 |
| SG\&A expenses | 2,229 | 25.6 | 2,300 | 27.7 | $\triangle 71$ | 96.9 |
| Operating income | 1,374 | 15.8 | 1,026 | 12.4 | 347 | 133.9 |
| Other income | 27 |  | 51 |  | $\triangle 23$ |  |
| Other expenses | 44 |  | 7 |  | 37 |  |
| Ordinary income | 1,357 | 15.6 | 1,071 | 12.9 | 286 | 126.7 |
| Extraordinary income | - |  |  |  | - |  |
| Extraordinary expenses | 1 |  |  |  | 1 |  |
| Income before income taxes | 1,356 | 15.6 | 1,071 | 12.9 | 285 | 126.6 |
| Corporation tax, etc. | 385 |  | 307 |  | 77 |  |
| (Tax burden) | 28.4\% |  | 28.7\% |  |  |  |
| Net income | 971 | 11.2 | 764 | 9.2 | 207 | 127.2 |
| EPS (total shares) | ¥29.73 |  | $¥ 23.38$ |  |  |  |
| EPS (minus treasury shares) | ¥32.68 |  | $¥ 25.28$ |  |  |  |
| Number of shares outstanding <br> Weighted-average number ot shares | 32,682,310 |  | 32,682,310 |  |  |  |
| outstanding (after deducting treasury shares) | 29,729,200 |  | 30,223,453 |  |  |  |


|  | $\begin{gathered} \text { Sept. } 2021 \\ \text { Interim Results } \end{gathered}$ |  | Sept. 2020 Interim Results |  | Year-on-Year Comparison |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Amount | \% of total | Amount | \% of total | Amount | \% |
| Net sales | 17,577 | 100.0 | 17,442 | 100.0 | 135 | 100.8 |
| Cost of Sales | 10,331 | 58.8 | 10,479 | 60.1 | $\triangle 147$ | 98.6 |
| Gross profit | 7,246 | 41.2 | 6,963 | 39.9 | 282 | 104.1 |
| SG\&A expenses | 4,483 | 25.5 | 4,581 | 26.3 | $\triangle 98$ | 97.9 |
| Operating income | 2,762 | 15.7 | 2,381 | 13.7 | 380 | 116.0 |
| Other income | 140 |  | 92 |  | 47 |  |
| Other expenses | 83 |  | 14 |  | 69 |  |
| Ordinary income | 2,819 | 16.0 | 2,459 | 14.1 | 359 | 114.6 |
| Extraordinary income | - |  | 1,028 |  | $\triangle 1,028$ |  |
| Extraordinary expenses | 1 |  | 1 |  | $\triangle 0$ |  |
| Income before income taxes | 2,817 | 16.0 | 3,486 | 20.0 | $\triangle 669$ | 80.8 |
| Corporation tax, etc. | 799 |  | 1,000 |  | $\triangle 200$ |  |
| (Tax burden) | 28.4\% |  | 28.7\% |  |  |  |
| Net income | 2,017 | 11.5 | 2,486 | 14.3 | $\triangle 468$ | 81.1 |
| EPS (total shares) | ¥61.73 |  | ¥76.08 |  |  |  |
| EPS (minus treasury shares) | ¥68.48 |  | ¥82.25 |  |  |  |
| Number of shares outstanding weignted-average number of shares | 32,682,310 |  | 32,682,310 |  |  |  |
| outstanding (after deducting treasury shares) | 29,461,490 |  | 30,228,126 |  |  |  |


| Third Quarter |  |  |  |  | millions, rounded down |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | $\begin{gathered} \text { Dec. } 2021 \\ \text { Interim Results } \end{gathered}$ |  | $\begin{gathered} \text { Dec. } 2020 \\ \text { Interim Results } \end{gathered}$ |  | $\begin{gathered} \text { Dec. } 2020 \\ \text { Interim Results } \end{gathered}$ |  |
|  | Amount | \% of total | Amount | \% of total | Amount | \% |
| Net sales | 27,256 | 100.0 | 27,214 | 100.0 | 41 | 100.2 |
| Cost of Sales | 16,038 | 58.8 | 16,213 | 59.6 | $\triangle 174$ | 98.9 |
| Gross profit | 11,217 | 41.2 | 11,001 | 40.4 | 216 | 102.0 |
| SG\&A expenses | 6,800 | 25.0 | 6,954 | 25.6 | $\triangle 154$ | 97.8 |
| Operating income | 4,416 | 16.2 | 4,046 | 14.9 | 370 | 109.2 |
| Other income | 374 |  | 354 |  | 19 |  |
| Other expenses | 133 |  | 22 |  | 111 |  |
| Ordinary income | 4,657 | 17.1 | 4,378 | 16.1 | 279 | 106.4 |
| Extraordinary income | 1 |  | 1,028 |  | $\triangle 1,027$ |  |
| Extraordinary expenses | 1 |  | 3 |  | $\triangle 1$ |  |
| Income before income taxes | 4,657 | 17.1 | 5,404 | 19.9 | $\triangle 746$ | 86.2 |
| Corporation tax, etc. | 1,322 |  | 1,550 |  | $\triangle 228$ |  |
| (Tax burden) | 28.4\% |  | 28.7\% |  |  |  |
| Net income | 3,335 | 12.2 | 3,853 | 14.2 | $\triangle 518$ | 86.5 |
| EPS (total shares) | ¥102.06 |  | ¥117.92 |  |  |  |
| EPS (minus treasury shares) | $\not \geqslant 114.05$ |  | ¥127.48 |  |  |  |
| Number of shares outstanding <br> Weighted-average number of shares | 32,682,310 |  | 32,682,310 |  |  |  |
| outstanding (after deducting treasury shares) | 29,245,790 |  | 30,232,009 |  |  |  |


| Full-year |  |  |  |  |  |  |  |  | millions, rounded down |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | $\begin{aligned} & \hline \text { Fiscal } 2021 \\ & \text { Results } \end{aligned}$ |  | $\begin{aligned} & \hline \text { Fiscal } 2020 \\ & \text { Results } \end{aligned}$ |  | Year-on-Year Comparison |  | Fiscal 2021 <br> Revised Plan |  | Revised Plan Comparison |  |
|  | Amount | \% of total | Amount | \% of total | Amount | \% | Amount | \% of total | Amount | \% |
| Net sales | 36,080 | 100.0 | 35,813 | 100.0 | 266 | 100.7 | 35,820 | 100.0 | 260 | 100.7 |
| Cost of Sales | 21,387 | 59.3 | 21,313 | 59.5 | 73 | 100.3 | 21,180 | 59.1 | 207 | 101.0 |
| Gross profit | 14,692 | 40.7 | 14,499 | 40.5 | 193 | 101.3 | 14,640 | 40.9 | 52 | 100.4 |
| SG\&A expenses | 9,031 | 25.0 | 9,455 | 26.4 | $\triangle 423$ | 95.5 | 9,210 | 25.7 | $\triangle 178$ | 98.1 |
| Operating income | 5,661 | 15.7 | 5,043 | 14.1 | 617 | 112.2 | 5,430 | 15.2 | 231 | 104.3 |
| Other income | 609 |  | 566 |  | 43 |  | 600 |  | 9 |  |
| Other expenses | 276 |  | 87 |  | 189 |  | 170 |  | 106 |  |
| Ordinary income | 5,993 | 16.6 | 5,522 | 15.4 | 470 | 108.5 | 5,860 | 16.4 | 133 | 102.3 |
| Extraordinary income | 1 |  | 1,028 |  | $\triangle 1,027$ |  |  |  | 1 |  |
| Extraordinary expenses | 1 |  | 28 |  | $\triangle 27$ |  | 10 |  | $\triangle 8$ |  |
| Income before income taxes | 5,994 | 16.6 | 6,522 | 18.2 | $\triangle 528$ | 91.9 | 5,850 | 16.3 | 144 | 102.5 |
| Corporation tax, etc. | 1,814 |  | 1,853 |  | $\triangle 39$ |  | 1,660 |  | 154 |  |
| (Tax burden) | 30.3\% |  | 29.0\% |  |  |  | 28.4\% |  |  |  |
| Net income | 4,179 | 11.6 | 4,669 | 13.0 | $\triangle 489$ | 89.5 | 4,190 | 11.7 | $\triangle 10$ | 99.8 |
| EPS (total shares) | ¥127.89 |  | $¥ 142.87$ |  |  |  | $¥ 128.20$ |  |  |  |
| EPS (minus treasury shares) | $¥ 146.33$ |  | $¥ 154.45$ |  |  |  | ¥146.69 |  |  |  |
| Number of shares outstanding weignted-average number or shares | 32,682,310 |  | 32,682,310 |  |  |  | 32,682,310 |  |  |  |
| outstanding (after deducting treasury shares) | 28,563,593 |  | 30,231,715 |  |  |  | 28,563,593 |  |  |  |

Fiscal 2021 Statements of Income by Half (Non-Consolidated)
Fiscal 2021 Results

|  | FIrst <br> Quarter | Second <br> Quarter | Ihird <br> Quarter | Fourth <br> Quarter |
| :--- | ---: | ---: | ---: | ---: |
| Net sales | 8,713 | 8,864 | 9,678 | 8,823 |
| Cost of Sales | 5,109 | 5,222 | 5,706 | 5,348 |
| Gross profit | 3,603 | 3,642 | 3,971 | 3,475 |
| SG\&A expenses | 2,229 | 2,254 | 2,317 | 2,230 |
| Operating income | 1,374 | 1,388 | 1,654 | 1,244 |
| Other income | 27 | 112 | 234 | 234 |
| Other expenses | 44 | 39 | 49 | 142 |
| Ordinary income | 1,357 | 1,461 | 1,838 | 1,336 |
| Extraordinary income | - | - | 1 | - |
| Extraordinary expenses | 1 | 0 | 0 | 0 |
| Income before income taxes | 1,356 | 1,460 | 1,840 | 1,336 |
| Corporation tax, etc. | 385 | 414 | 522 | 491 |
| (Tax burden) | $28.4 \%$ | $28.4 \%$ | $28.4 \%$ | $36.8 \%$ |
| Net income | 971 | 1,046 | 1,317 | 844 |

$¥$ millions, rounded down

| First Half | Thira Quarter <br> (Cumulative) | Full-year |
| ---: | ---: | ---: |
| 17,577 | 27,256 | 36,080 |
| 10,331 | 16,038 | 21,387 |
| 7,246 | 11,217 | 14,692 |
| 4,483 | 6,800 | 9,031 |
| 2,762 | 4,416 | 5,661 |
| 140 | 374 | 609 |
| 83 | 133 | 276 |
| 2,819 | 4,657 | 5,993 |
| - | 1 | 1 |
| 1 | 1 | 1 |
| 2,817 | 4,657 | 5,994 |
| 799 | 1,322 | 1,814 |
| $28.4 \%$ | $28.4 \%$ | $30.3 \%$ |
| 2,017 | 3,335 | 4,179 |
|  |  |  |

Fiscal 2020 Results

|  | First <br> Quarter | Second <br> Quarter | Third <br> Quarter | Fourth <br> Quarter |
| :---: | ---: | ---: | ---: | ---: |
| Net sales | 8,292 | 9,150 | 9,771 | 8,598 |
| Cost of Sales | 4,965 | 5,513 | 5,733 | 5,100 |
| Gross profit | 3,327 | 3,636 | 4,037 | 3,498 |
| SG\&A expenses | 2,300 | 2,281 | 2,372 | 2,500 |
| Operating income | 1,026 | 1,354 | 1,664 | 997 |
| Other income | 51 | 40 | 262 | 211 |
| Other expenses | 7 | 7 | 8 | 64 |
| Ordinary income | 1,071 | 1,387 | 1,919 | 1,144 |
| Extraordinary income | - | 1,028 | - | -1 |
| Extraordinary expenses | - | 1 | 1 | 25 |
| Income before income taxes | 1,071 | 2,415 | 1,917 | 1,118 |
| Corporation tax, etc. | 307 | 692 | 550 | 302 |
| (Tax burden) | $28.7 \%$ | $28.7 \%$ | $28.7 \%$ | $27.1 \%$ |
| Net income | 764 | 1,722 | 1,367 | 815 |


| First Half | ThirdQuarter <br> (Cumulative) | Full-year |
| ---: | ---: | ---: |
| 17,442 | 27,214 | 35,813 |
| 10,479 | 16,213 | 21,313 |
| 6,963 | 11,001 | 14,499 |
| 4,581 | 6,954 | 9,455 |
| 2,381 | 4,046 | 5,043 |
| 92 | 354 | 566 |
| 14 | 22 | 87 |
| 2,459 | 4,378 | 5,522 |
| 1,028 | 1,028 | 1,028 |
| 1 | 3 | 28 |
| 3,486 | 5,404 | 6,522 |
| 1,000 | 1,550 | 1,853 |
| $28.7 \%$ | $28.7 \%$ | $28.4 \%$ |
| 2,486 | 3,853 | 4,669 |

## Change(Amount)

|  | $\begin{gathered} \text { First } \\ \text { Quarter } \end{gathered}$ | Second Quarter | $\begin{aligned} & \text { Third } \\ & \text { Quarter } \end{aligned}$ | Fourth Quarter |
| :---: | :---: | :---: | :---: | :---: |
| Net sales | 420 | $\triangle 285$ | $\triangle 93$ | 225 |
| Cost of Sales | 144 | $\triangle 291$ | $\triangle 26$ | 248 |
| Gross profit | 276 | 6 | $\triangle 66$ | $\triangle 22$ |
| SG\&A expenses | $\triangle 71$ | $\triangle 27$ | $\triangle 55$ | $\triangle 269$ |
| Operating income | 347 | 33 | $\triangle 10$ | 246 |
| Other income | $\triangle 23$ | 71 | $\triangle 28$ | 23 |
| Other expenses | 37 | 32 | 41 | 78 |
| Ordinary income | 286 | 73 | $\triangle 80$ | 191 |
| Extraordinary income | - | $\triangle 1,028$ | 1 |  |
| Extraordinary expenses | 1 | $\triangle 1$ | $\triangle 1$ | $\triangle 25$ |
| Income before income taxes | 285 | $\triangle 954$ | $\triangle 77$ | 217 |
| Corporation tax, etc. | 77 | $\triangle 278$ | $\triangle 27$ | 188 |
| (Tax burden) |  |  |  |  |
| Net income | 207 | $\triangle 676$ | $\triangle 49$ | 28 |


| First Half | Third Quarter <br> (Cumulative) | Full-year |
| ---: | ---: | ---: |
| 135 | 41 | 266 |
| $\triangle 147$ | $\triangle 174$ | 73 |
| 282 | 216 | 193 |
| $\triangle 98$ | $\triangle 154$ | $\triangle 423$ |
| 380 | 370 | 617 |
| 47 | 19 | 43 |
| 69 | 111 | 189 |
| 359 | 279 | 470 |
| $\triangle 1,028$ | $\triangle 1,027$ | $\triangle 1,027$ |
| $\triangle 0$ | $\triangle 1$ | $\triangle 27$ |
| $\triangle 669$ | $\triangle 746$ | $\triangle 528$ |
| $\triangle 200$ | $\triangle 228$ | $\triangle 39$ |
|  |  |  |
| $\triangle 468$ | $\triangle 518$ | $\triangle 489$ |

## Change(\%)

|  | First <br> Quarter | Second <br> Quarter | Third <br> Quarter | Fourth <br> Quarter |
| :--- | ---: | ---: | ---: | ---: |
| Net sales | 105.1 | 96.9 | 99.0 | 102.6 |
| Cost of Sales | 102.9 | 94.7 | 99.5 | 104.9 |
| Gross profit | 108.3 | 100.2 | 98.4 | 99.3 |
| SG\&A expenses | 96.9 | 98.8 | 97.7 | 89.2 |
| Operating income | 133.9 | 102.5 | 99.4 | 124.7 |
| Other income |  |  |  |  |
| Other expenses |  |  |  |  |
| Ordinary income | 126.7 | 105.3 | 95.8 | 116.8 |
| Extraordinary income |  |  |  |  |
| Extraordinary expenses |  |  |  |  |
| Income before income taxes | 126.6 | 60.5 | 96.0 | 119.5 |
| Corporation tax, etc. |  |  |  |  |
| (Tax burden) |  |  |  |  |
| Net income | 127.2 | 60.7 | 96.4 | 103.5 |


| First Half | Third Quarter <br> (Cumulative) | Full-year |
| ---: | ---: | ---: |
| 100.8 | 100.2 | 100.7 |
| 98.6 | 98.9 | 100.3 |
| 104.1 | 102.0 | 101.3 |
| 97.9 | 97.8 | 95.5 |
| 116.0 | 109.2 | 112.2 |
|  |  |  |
|  |  |  |
| 114.6 | 106.4 | 108.5 |
|  |  |  |
|  |  |  |
| 80.8 | 86.2 |  |
|  |  | 91.9 |
|  |  |  |
| 81.1 | 86.5 |  |
|  |  | 89.5 |

## Breakdown

| First Half | (hira Quarter <br> (Cumulative) | Full-year |
| ---: | ---: | ---: |
| 100.0 | 100.0 | 100.0 |
| 58.8 | 58.8 | 59.3 |
| 41.2 | 41.2 | 40.7 |
| 25.5 | 25.0 | 25.0 |
| 15.7 | 16.2 | 15.7 |
|  |  |  |
|  |  |  |
| 16.0 | 17.1 | 16.6 |
|  |  |  |
|  |  |  |
| 16.0 | 17.1 | 16.6 |
|  |  |  |
|  |  |  |
| 11.5 | 12.2 | 11.6 |

Fiscal 2022 Projected Statements of Income (Non-Consolidated)
Cumulative
¥ millions, rounded down,(\%)

|  | First Half | \% of total | Full-year | \% of total |
| :---: | :---: | :---: | :---: | :---: |
| Net sales | 18,770 | 100.0 | 38,100 | 100.0 |
| Operating income | 3,060 | 16.3 | 6,060 | 15.9 |
| Ordinary income | 3,090 | 16.5 | 6,320 | 16.6 |
| Net income | 2,150 | 11.5 | 4,410 | 11.6 |
| EPS (before deducting treasury shares) | $¥ 65.78$ |  | $¥ 134.94$ |  |
| EPS (minus treasury shares) | $¥ 88.63$ |  | $¥ 181.80$ |  |
|  | Number of shares outstanding |  | 32,682,310 |  |
|  | Shares outstanding at FY2021year-end |  | 24,257,103 |  |
| Fiscal 2021 Results | (deducting treasury shares) |  |  |  |
| Net sales | 17,577 | 100.0 | 36,080 | 100.0 |
| Operating income | 2,762 | 15.7 | 5,661 | 15.7 |
| Ordinary income | 2,819 | 16.0 | 5,993 | 16.6 |
| Net income | 2,017 | 11.5 | 4,179 | 11.6 |

Change (Amount and \%)

| Net sales | 1,192 | 106.8 | 2,019 | 105.6 |
| :--- | ---: | ---: | ---: | ---: |
| Operating income | 297 | 110.8 | 398 | 107.0 |
| Ordinary income | 270 | 109.6 | 326 | 105.4 |
| Net income | 132 | 106.6 | 230 | 105.5 |

Total Manufacturing Costs (Non-Consolidated )
$¥$ millions, rounded down

|  | FY 2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY 2018 | FY2019 | FY2020 | FY2021 | Plan FY2022 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Materials | 10,295 | 10,821 | 11,728 | 12,545 | 12,945 | 12,803 | 12,769 | 12,765 | 12,883 | 12,287 | 13,956 |
| Personnel | 1,761 | 1,882 | 1,797 | 1,795 | 1,742 | 1,713 | 1,661 | 1,658 | 1,750 | 1,748 | 1,836 |
| Outsourcing | 367 | 414 | 389 | 406 | 411 | 398 | 412 | 369 | 390 | 367 | 376 |
| Depreciation expenses | 1,868 | 1,603 | 1,370 | 1,969 | 3,081 | 5,035 | 4,392 | 3,974 | 3,385 | 3,030 | 3,285 |
| Others | 1,460 | 1,512 | 1,492 | 1,466 | 1,755 | 1,910 | 2,209 | 2,139 | 2,116 | 2,275 | 2,135 |
| Total | 15,752 | 16,234 | 16,779 | 18,183 | 19,935 | 21,861 | 21,445 | 20,907 | 20,527 | 19,709 | 21,589 |

## Increase Rate

(\%)

|  | FY 2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY 2018 | FY2019 | FY2020 | FY2021 |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Plan FY2022 |  |  |  |  |  |  |  |  |  |  |
| Materials | 106.0 | 105.1 | 108.4 | 107.0 | 103.2 | 98.9 | 99.7 | 100.0 | 100.9 | 95.4 |
| Personnel | 98.9 | 106.9 | 95.5 | 99.9 | 97.1 | 98.3 | 97.0 | 99.8 | 105.6 | 99.8 |
| Outsourcing | 99.7 | 112.9 | 93.9 | 104.4 | 101.1 | 96.9 | 103.4 | 89.6 | 105.8 | 94.1 |
| Depreciation expenses | 88.9 | 85.8 | 85.5 | 143.7 | 156.4 | 163.4 | 87.2 | 90.5 | 85.2 | 89.5 |
| Others | 99.6 | 103.5 | 98.7 | 98.2 | 119.7 | 108.9 | 115.6 | 96.8 | 98.9 | 107.5 |
| Total | 102.1 | 103.1 | 103.4 | 108.4 | 109.6 | 109.7 | 98.1 | 97.5 | 98.2 | 96.0 |

Composition Rate

|  | FY 2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY 2018 | FY2019 | FY2020 | FY2021 | Plan FY2022 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Materials | 65.4 | 66.7 | 69.9 | 69.0 | 64.9 | 58.6 | 59.5 | 61.1 | 62.8 | 62.3 | 64.6 |
| Personnel | 11.2 | 11.6 | 10.7 | 9.9 | 8.7 | 7.8 | 7.7 | 7.9 | 8.5 | 8.9 | 8.5 |
| Outsourcing | 2.3 | 2.6 | 2.3 | 2.2 | 2.1 | 1.8 | 1.9 | 1.8 | 1.9 | 1.9 | 1.7 |
| Depreciation expenses | 11.9 | 9.9 | 8.2 | 10.8 | 15.5 | 23.0 | 20.5 | 19.0 | 16.5 | 15.4 | 15.2 |
| Others | 9.3 | 9.3 | 8.9 | 8.1 | 8.8 | 8.7 | 10.3 | 10.2 | 10.3 | 11.5 | 9.9 |
| Total | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 |



Composition Rate



[^0]:    Fiscal 2005 Operamaster expansion line : 1,469, New distribution center : 1,947
    Fiscal 2006 New distribution center : 886
    Fiscal 2007 Industrial-use land: 973
    Fiscal 2008 Industrial-use land : 752, Sterilization equipment: 876 ,Indonesia factory : 381
    Fiscal 2009 Sterilization equipment : 1,833,Indonesia factory : 995
    Fiscal 2010 Sterilization equipment : 2,732
    Fiscal 2013 New plant construction costs : 5,166
    Fiscal 2014 New plant construction costs : 8,113. New plant equipment costs : 4,567
    Fiscal 2015 New plant : 7,300
    Fiscal 2016 New plant : 5,981
    Fiscal 2019 New plant additional investment : 9,512
    Fiscal 2020 New plant additional investment : 3,644
    Fiscal 2021 New plant additional investment : 1,830

